Resources

Resources

Infographic

Specialty Product Launch: Data and Analytics Strategy Checklist

IntegriChain has helped a number of leading specialty brands across therapeutic areas develop and implement a specialty data & analytics strategy for launch. We've consolidated a list of best practices including SP data contracting, de-identification/tokenization, data quality, data warehouse integration, and patient journey analytics...

View Infographic

Webinar

Pricing Transparency: Building a Compliance Framework

This webinar discusses some of the new pricing laws coming online as well as adjustments to consider in your compliance monitoring framework. Webinar attendees will receive information on key legislative trends, understand implications on pricing and launch programs and review key elements of a...

View Webinar

Blog

5 Steps to a Better Specialty Data Contracting Strategy

An effective specialty data contracting strategy starts at the finish line and works backward. The decisions made in terms of data fields, sub-status granularity, reporting frequency, and contact language, determine the metric outputs that are possible. This post looks at how the right specialty...

Read Blog Post

Blog

Utilizing AI and Machine Learning to Predict Challenging Patient Cases

IntegriChain is utilizing AI and machine learning to develop risk score models that will allow Field Reimbursement Managers (FRMs) and similar functions to proactively intervene on behalf of patients who are likely to experience roadblocks in their journey -- before the roadblocks occur. Predictive...

Read Blog Post

Article

Using Patient Journey Insights to Tailor Delivery of Services

In 2018, the US FDA approved 63 novel drugs and biologics—and a staggering 44 of the approved products are considered specialty. The prevalence of specialty products launching and progressing through the development pipeline is giving rise to a nearly equal number of Patient Support...

Read Article

Blog

Cancellation Reasons Highlight the Opportunity to Proactively Support Stalled Patient Cases

The quality of status and sub-status data reported by SPs is an ongoing challenge that limits the actionability of data specialty brands have contracted to receive. Clearly, poor data quality limits the level of insights that analytics can surface for key stakeholders. Simply cleansing...

Read Blog Post

Webinar

The Opportunity for Data Science to Improve Patient Adherence

This webinar takes a deep dive into analytics that identify highlight (and predict) the drivers of primary and secondary medication non-adherence. We'll explore how diagnostic insights can help your teams identify and act on the patient journey barriers that delay therapy initiation and negatively...

View Webinar

Webinar

Challenges of Integrating Specialty Pharmacy Data, Syndicated Claims and Channel Data

Please join us for this session in our Access Insights webinar series exploring the challenges of calculating total inventory pipeline for specialty products. In this webinar, we will be joined by a few of IntegriChain's top Subject Matter Experts who will discuss their first...

View Webinar

Infographic

Specialty Pharmacy Patient Data Excellence

Poor quality SP data is preventing brands from taking actions that help patients start on therapy faster and stay on therapy longer. What are the steps required to improve data quality and achieve true patient journey visibility? Through our work with leading specialty brands...

View Infographic

Webinar

Gross-to-Net Roadmap to Launch

The Roadmap to Launch webinar is a comprehensive countdown of the key gross-to-net (GTN) milestones your team needs to achieve as you prepare for launch. During this webinar we'll share specific insights from companies like yours to highlight different approaches to the most complex...

View Webinar

Webinar

GTN Automation Series: Leveraging Distribution Data for More Powerful Pipeline and Returns Reserves

Please join us for the first session in our webinar series exploring the benefits, trends, and winning strategies for Gross-to-Net Automation. We begin this series by reiterating best practices and exploring modern options for automating and optimizing channel distribution datasets when setting pipeline and...

View Webinar

Webinar

Launch Readiness for Commercial Contracting and Government Programs: Coverage & Policy Trends

Join us for the first in a series of webinars focused on Access Launch Readiness. We’ll start this series with our new daVIZta colleagues for a great entry point for emerging Life Sciences manufacturers who are planning their launch within the next two years....

View Webinar

Webinar

Strategies for Data-Driven Field Reimbursement Teams

Facilitating patient access to prescribed specialty therapeutics continues to be a challenge in a difficult managed care environment. Patients need help navigating obstacles that delay therapy initiation, such as prior authorization and rising out-of-pocket costs, and cause interruptions in treatment. Field Reimbursement (FRM) teams...

View Webinar

Webinar

The Current State of Specialty Patient Status Data and How Specialty Brands Can Improve Data Quality

Missing patient status updates, limited granularity, and inaccurate information all contribute to poor patient journey visibility. A lack of insights into each individual patient journey make it exceedingly difficult to manage a specialty brand. How then, can specialty brands cultivate true patient journey insights...

View Webinar

Webinar

Specialty Pharmacy Data Strategy: Contracting for the Right Data

How will you use analytics to measure commercial success and improve patient experience for your specialty brand? An effective specialty data contracting strategy starts at the finish line and works backward. The decisions you make in terms of data fields, sub-status granularity, reporting frequency,...

View Webinar

Blog

Opioid Crisis Exposes Vulnerabilities in Suspicious Order Monitoring

The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharma manufacturers are now facing increased scrutiny and need a new approach to suspicious order monitoring. In this post, IntegriChain Solutions Principal...

Read Blog Post

Webinar

How to Self Police Revenue Leakage due to 340B Program Non-Compliance

There is broad agreement across the pharmaceutical industry and Congress that that 340B program needs more oversight and statutory change. But with so much congressional paralysis and midterm elections on the horizon, it’s highly unlikely that changes will occur anytime soon. The status quo...

View Webinar

Blog

3 Key Opportunities to Improve Specialty Patient Initiation

Prior Authorization (PA) is required for nearly all specialty products and is largely responsible for delayed patient initiation. Lengthy PA delays can ultimately result in cancellations for new patient referrals, adherence/persistence problems, and lower patient satisfaction. There are several ways specialty brands can improve...

Read Blog Post

Blog

The Economics of Rare Disease and Implications for Payer Contract Strategy

Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these...

Read Blog Post

Infographic

Commercial Readiness Timeline

Based on our experience as the access operations team and data platform for more than 100 pharma companies that are launching novel drugs in the US, we've developed a Commercial Readiness Timeline guide--taking you from 12-months pre-launch for readiness to 12-months post-launch for commercialization--that...

View Infographic

Paper

Using Market Analogs for FP&A During Product Launch

Estimating the value of net sales adjustments from a Finance perspective can be very difficult due to a lack of available data and market information. The problem is especially acute before launch and in the first few quarters the product is on the market....

Download Paper

Webinar

Formulary and Contract Compliance – Uncover Rebate Savings and Reduce Financial Risk

IntegriChain Market Access has been able to leverage subject matter expertise, tools, and techniques to identify between 1.25% and 2.5% of a payers' total rebate spend as non-compliant. In this webinar, our in-house experts John Still and Tina Cullen highlight how two critical compliance...

View Webinar

Webinar

Best Practices in Specialty Data Services Contracts

The expansion of specialty networks to include more pharmacies, and the growing complexity within these networks, is forcing manufacturers to make trade offs as they contract for data critical to understanding and impacting the patient journey. In this webinar, we look at how the...

View Webinar

Webinar

Contracting & Pricing Product Launch Strategies for Small- and Mid-Sized Pharma

The list of challenges associated with commercializing a product is long and diverse. Every decision seems to affect patient access to your product and has long-term implications on growth and profitability. Too often manufacturers make commercialization decisions, negotiate agreements, and set prices that aren't...

View Webinar

Webinar

Controlling Risks through Order Management: Addressing Price Transparency Laws and the Opioid Crisis

The need for the type of accountability provided by order management technology has never been greater. Price Transparency legislation passed in a handful of states in 2017, including California. Additional states are working on their own bills. These laws have the potential to encourage...

View Webinar

Webinar

Reducing Revenue Leakage with Chargeback Analytics

Automated chargeback applications execute many important validations such as contract eligibility, membership verification, and price checks. Nonetheless the most obvious sources of revenue leakage, sales and return unit quantities, are not checked at all.  One example of potential loss occurs when a trade partner receives...

View Webinar

Webinar

Using Analytics to Identify High Value, Under Indexed Retail Pharmacies

Multiple factors are challenging patients as they seek access to innovative brands at the retail pharmacy. Complicated payer/plan policy restrictions, including prior authorizations, often delay initiation of therapy. Escalating out-of-pocket costs are another obstacle patients must navigate. This webinar highlights how IntegriChain Retail Analytics...

View Webinar

Case Study

Optimize Rebate Investments with PBMs & HMOs

A manufacturer had historically based Managed Care pricing decisions on highly subjective information and emotion rather than historical data on customer and contract performance. Limited and inaccurate data led to impromptu “how are we doing?” check-in calls. As a result, members of the Pricing...

Read Case Study

Case Study

Improving Managed Care ROI

A disconnect existed between the contract negotiation business function and the contract analyst business function. The belief was that contract performance was not meeting expectations set at the outset of the agreement. We applied a Rational Pricing methodology to help the manufacturer determine if...

Read Case Study

Article

Use Data Analytics to Monitor 340B Discount Drug Pricing

As the industry refocuses on more innovative, expensive specialty drugs and channel designs shift, however, manufacturers are growing increasingly concerned with the 340B Drug Discount Program. Analytics will help manufacturers in their quest to discern how and where products are discounted.

Read Article

Paper

The Value of the 1%

Manufacturers know that ensuring product availability is very difficult, especially when product distribution is so expensive. Further complicating matters, sales do not equal demand, leading to a real commerce optimization problem within the demand network.

Download Paper

eBook

Leaving the Legacy

Pharmaceutical manufacturers continue to struggle with ensuring product availability, controlling distribution cost, and increasing forecast accuracy. This is often because they are using outdated or constrained legacy platforms. In this ebook, learn how three of our customers moved away from disparate systems to IntegriChain’s...

Download eBook

eBook

Mobile-Optimized Channel Management and Demand Sensing Analytics

The latest release of the IntegriChain channel management cloud offers mobile user access and near real-time demand sensing to maximize the accessibility and value of channel data through the life sciences supplier enterprise.

Download eBook

Webinar

Using Channel Data Analytics for 340B Monitoring and Audit Support

IntegriChain Director of Solution Engineering Dave Weiss and guest speaker Michael Townsend, IDC Health Insights Research Manager, Life Sciences Business Systems Strategies explore the changing breadth of the 340B Discount Drug Program and the insights offered in the Health Resources and Services Administration’s (HRSA’s) recently released mega-guidance, including results...

View Webinar

Webinar

Outside-In Order Management

IntegriChain and Lora Cecere, Founder & CEO of Supply Chain Insights, take a deep dive into the new “outside-in” methodology of using actual channel data to make informed order decisions. Lora focuses on how suppliers can use advanced analytics to sense order flows and...

View Webinar

eBook

The Impact of Downstream Inventory on Gross-to-Net Accounting

In this webinar, we explore best practices for estimating inventory when calculating gross-to-net to eliminate gross overstatements or understatements of pipeline liabilities that do not triangulate well with other commercial commerce datasets. Attendees will learn about best practices for using auditor-approved downstream inventory data...

Download eBook

Webinar

IntegriChain Builder Intelligence Tool

Builder radically improves the actionability of channel analytics, driving down the cost of total ownership of wholesaler and specialty data sources while maximizing the value of manufacturer investments in data agreements. This webinar covers merging disparate data sources into one report or visualization, manipulating...

View Webinar

Article

Finding the Value in Outsourced Contract Administration

The growing complexity of managed markets contract support makes outsourcing a near-necessity for emerging pharmaceutical companies, and a better option for big pharma.

Read Article

eBook

The Value of 1%

Manufacturers know that ensuring product availability is very difficult, especially when product distribution is so expensive. Further complicating matters, sales do not equal demand, leading to a real commerce optimization problem within the demand network. Download The Value of 1% White Paper to explore...

Download eBook

eBook

Daily Business Management Trade & Channel

In today’s era of Pay-for-Performance agreements and lean channel inventory, pharmaceutical manufacturers want to know how to better align product availability with the overall cost of distribution. The answer can be found in a new approach to trade data utilization called Daily Business Management....

Download eBook

Blog

Leveraging Distributor Contract Management to Optimize Evolving DSAs

As distribution service agreements evolve over time, manufacturers must have the ability to run what-if analyses on actual scorecard data to analyze the overall effect various changes under consideration would have on trade partner payments. In this post, we look at how Distributor Contract...

Read Blog Post

Blog

Specialty Pharmacy Status/Sub-Status Analysis Highlights Inconsistencies in Data Quality

IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory....

Read Blog Post

Webinar

Unlock the Power of Scorecard Analytics to Maximize Pay-for-Performance

This webinar covers major enhancements to trade partner scorecard functionality found within IntegriChain Distribution Analytics. These enhancements allow Scorecard users to utilize robust trade partner agreement data to further maximize pay-for-performance by analyzing channel investment against performance through IntegriChain's powerful Data on Demand and...

View Webinar

Article

How Not to Handle Rebates

As financial pressures increase, pharmaceutical companies are paying greater attention to cutting costs and increasing efficiency. However, rebate expenditures continue to expand.

Read Article

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand